포토옹
포토옹님이 쓴 글 모음
Oscotec Inc. Joins the United Nations Global Compact (UNGC)
Oct 19, 2026
Oscotec Inc. would like to express its sincere gratitude to all shareholders and stakeholders for their continued interest and support. In October 2026, Oscotec Inc. joined the United Nations Global Compact (UNGC) as part of its commitment to advancing sustainable...
Oscotec 2025 ESG FACT Book
Sep 28, 2026
Oscotec has published "the Oscotec 2025 ESG Fact Book" to disclose our key ESG achievements and information more transparently and to strengthen communication with our stakeholders. This Fact Book is based on performance from January 1 to December 31, 2025, and...
Oscotec ESG (Environmental, Social, and Governance) Management Policy
Sep 28, 2026
At Oscotec, we have established and published an “ESG Management Policy Book” that outlines our management principles and standards of practice across the environment, society, and governance to pursue sustainable growth and faithfully fulfill our corporate social...
Oscotec to Participate in BIO USA, Seeking Global Partnerships for Next-Generation Pipelines
Aug 24, 2026
Youngshin Kwak, Head of Oscotec Research Institute: “We Will Compete with Anti-Resistance Cancer Therapy Within 3 Years” [BioUSA]
Aug 24, 2026
Oscotec Inc. Q2 2026 Factsheet
Aug 19, 2026
OCT-598, a novel EP2/EP4 dual antagonist, promotes anti-tumor immune response in syngeneic mouse tumor models in combination with standard-of-care chemo- and immunotherapies
Aug 6, 2026
Abstract 3234: OCT-598, a novel EP2/EP4 dual antagonist, promotes anti-tumor immune responses in syngeneic mouse tumor models in combination with standard-of-care chemo- and immunotherapies Prostaglandin E2 (PGE2) is widely recognized as one of the major bioactive...
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer
Jul 22, 2026
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer
YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC
Jul 22, 2026
YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC
Subscribe
and get the latest updates